Literature DB >> 19789317

Rapid development of hypertension by sorafenib: toxicity or target?

Benjamin D Humphreys1, Michael B Atkins.   

Abstract

Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19789317      PMCID： PMC2762358          DOI： 10.1158/1078-0432.CCR-09-1717

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Authors:  Tejas V Patel; Jeffrey A Morgan; George D Demetri; Suzanne George; Robert G Maki; Michael Quigley; Benjamin D Humphreys
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

2.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability.

Authors:  D Fukumura; T Gohongi; A Kadambi; Y Izumi; J Ang; C O Yun; D G Buerk; P L Huang; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

3.  Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

Authors:  J R Horowitz; A Rivard; R van der Zee; M Hariawala; D D Sheriff; D D Esakof; G M Chaudhry; J F Symes; J M Isner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

4.  Autocrine VEGF signaling is required for vascular homeostasis.

Authors:  Sunyoung Lee; Tom T Chen; Chad L Barber; Maria C Jordan; Jared Murdock; Sharina Desai; Napoleone Ferrara; Andras Nagy; Kenneth P Roos; M Luisa Iruela-Arispe
Journal:  Cell       Date:  2007-08-24       Impact factor: 41.582

5.  Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Authors:  Michael L Maitland; Kristen E Kasza; Theodore Karrison; Kristin Moshier; Laura Sit; Henry R Black; Samir D Undevia; Walter M Stadler; William J Elliott; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

6.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

7.  Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?

Authors:  Rachel Schor-Bardach; David C Alsop; Ivan Pedrosa; Stephanie A Solazzo; Xiaoen Wang; Robert P Marquis; Michael B Atkins; Meredith Regan; Sabina Signoretti; Robert E Lenkinski; S Nahum Goldberg
Journal:  Radiology       Date:  2009-06       Impact factor: 11.105

8.  Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Authors:  Neeltje Steeghs; Hans Gelderblom; Jos Op 't Roodt; Olaf Christensen; Prabhu Rajagopalan; Marcel Hovens; Hein Putter; Ton J Rabelink; Eelco de Koning
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

9.  Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.

Authors:  M E Lacouture; L M Reilly; P Gerami; J Guitart
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976

10.  Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.

Authors:  Pamela H Franklin; Patricia N Banfor; Paul Tapang; Jason A Segreti; Deborah L Widomski; Kelly J Larson; William T Noonan; Gary A Gintant; Steven K Davidsen; Daniel H Albert; Ryan M Fryer; Bryan F Cox
Journal:  J Pharmacol Exp Ther       Date:  2009-03-02       Impact factor: 4.030
  10 in total
  23 in total

1.  Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition.

Authors:  Sarah B Sunshine; Susan M Dallabrida; Ellen Durand; Nesreen S Ismail; Lauren Bazinet; Amy E Birsner; Regina Sohn; Sadakatsu Ikeda; William T Pu; Matthew H Kulke; Kashi Javaherian; David Zurakowski; Judah M Folkman; Maria Rupnick
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

Review 2.  Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Authors:  Rodrigo Dienstmann; Irene Braña; Jordi Rodon; Josep Tabernero
Journal:  Oncologist       Date:  2011-12-01

3.  The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).

Authors:  Hilda Wong; Yuen Fong Tang; Tzy-Jyun Yao; Joanne Chiu; Roland Leung; Pierre Chan; Tan To Cheung; Albert C Chan; Roberta W Pang; Ronnie Poon; Sheung-Tat Fan; Thomas Yau
Journal:  Oncologist       Date:  2011-12-01

Review 4.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

Authors:  Emily S Robinson; Eliyahu V Khankin; S Ananth Karumanchi; Benjamin D Humphreys
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

Review 5.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

6.  The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: the influence of liver fibrosis.

Authors:  Masayoshi Yada; Masayuki Miyazaki; Kenta Motomura; Akihide Masumoto; Makoto Nakamuta; Motoyuki Kohjima; Rie Sugimoto; Yoshifusa Aratake; Nobuhiko Higashi; Shusuke Morizono; Shinichiro Takao; Naoki Yamashita; Takeaki Satoh; Shinsaku Yamashita; Masami Kuniyoshi; Kazuhiro Kotoh
Journal:  J Gastrointest Oncol       Date:  2016-08

7.  Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

Authors:  Emily S Robinson; Ursula A Matulonis; Percy Ivy; Suzanne T Berlin; Karin Tyburski; Richard T Penson; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

8.  Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.

Authors:  Noriyuki Akutsu; Shigeru Sasaki; Hideyasu Takagi; Masayo Motoya; Masahiro Shitani; Mai Igarashi; Daisuke Hirayama; Hideki Wakasugi; Hiroyuki Yamamoto; Hiroyuki Kaneto; Kazuhiko Yonezawa; Atsushi Yawata; Takeya Adachi; Yasuo Hamamoto; Yasuhisa Shinomura
Journal:  Int J Clin Oncol       Date:  2014-04-18       Impact factor: 3.402

9.  Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor-Binding Protein).

Authors:  Elena Tassi; En Yin Lai; Lingli Li; Glenn Solis; Yifan Chen; William E Kietzman; Patricio E Ray; Anna T Riegel; William J Welch; Christopher S Wilcox; Anton Wellstein
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

10.  Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.

Authors:  Akihiro Yamasaki; Narihiro Umeno; Shigeru Harada; Kosuke Tanaka; Masaki Kato; Kazuhiro Kotoh
Journal:  J Gastrointest Oncol       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.